List of Rasuvo drug patents
Rasuvo is owned by Medexus.
Rasuvo contains Methotrexate.
Rasuvo has a total of 1 drug patent out of which 0 drug patents have expired.
Rasuvo was authorised for market use on 10 July, 2014.
Rasuvo is available in solution;subcutaneous dosage forms.
Rasuvo can be used as subcutaneous injection of methotrexate.
The generics of Rasuvo are possible to be released after 01 June, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8664231 | MEDEXUS | Concentrated methotrexate solutions |
Jun, 2029
(6 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 10 July, 2014
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic